EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry

Rafat Abonour, Hans C Lee, Robert Rifkin, Sikander Ailawadhi, James Omel, James W Hardin, Mohit Narang, Kathleen Toomey, Cristina Gasparetto, Lynne I Wagner, Howard Terebelo, Jorge Mouro und 4 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2024.05.021 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Rafat Abonour und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, Indiana University, Indianapolis, IN. Electronic address: rabonour@iu.edu. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Dexamethasone, Lenalidomide. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lenalidomide (R), bortezomib (V), and dexamethasone (d) is a standard-of-care regimen in newly diagnosed multiple myeloma (NDMM); however, characteristics and outcomes for nontransplanted patients receiving frontline RVd are not well understood. PATIENTS: The ConnectⓇ MM Registry is a large, US, multicenter, prospective observational cohort study of NDMM patients. METHODS: This analysis investigated characteristics and outcomes of patients who received RVd alone or followed by Rd or R (RVd ± Rd/R) who did not undergo frontline autologous stem cell transplantation. RESULTS: As of August 2021, 314 of 1979 nontransplanted patients received RVd ± Rd/R as initial therapy. Of these, 135 were aged ≤ 65 years and 179 were > 65 years. 108 patients had time to relapse (TTR) of ≤ 12 months and 182 had TTR > 12 months. Baseline characteristics were comparable regardless of TTR and age group except renal function, which was more commonly impaired in older patients. Among patients aged ≤ 65 and > 65 years, median duration of first-line treatment was 6.3 and 9.0 months, median time to next line for those who received second-line therapy was 15.5 and 15.2 months, median progression-free survival (PFS) was 19.3 and 23.0 months, and median overall survival was 60.0 and 59.1 months, respectively. High-risk disease (per IMWG criteria) and high serum calcium were associated with higher hazard of progression or death; the adjusted PFS hazard ratio with respect to age (≤ 65 vs. > 65 years) based on multivariable analysis was 1.18 (0.89-1.57; P = .25). CONCLUSION: These results indicate RVd is active across age groups and provide a better understanding of outcomes with RVd in NDMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneLenalidomideMultiple MyelomaRegistriesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAge FactorsProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

Autologous stem cell transplantationFrontlineMultiple myelomaRVdReal-world

Substanzen

BortezomibDexamethasoneLenalidomide

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, Indiana University, Indianapolis, IN. Electronic address: rabonour@iu.edu.
  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Rocky Mountain Cancer Centers US Oncology, Denver, CO.
  • Department of Hematology, Mayo Clinic, Jacksonville, FL.
  • Myeloma Research Advocate/Advisor, Grand Island, NE.
  • Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC.

Zitieren

APA

Abonour, R., Lee, H. C., Rifkin, R., Ailawadhi, S., Omel, J., Hardin, J. W., Narang, M., Toomey, K., Gasparetto, C., Wagner, L. I., Terebelo, H., Mouro, J., Dhanasiri, S., Liu, L., Yu, E., & Jagannath, S. (2024). The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.05.021

Vancouver

Abonour R, Lee HC, Rifkin R, Ailawadhi S, Omel J, Hardin JW, et al. The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.05.021

BibTeX
@article{Abonour2024,
  author = {Abonour, Rafat and Lee, Hans C and Rifkin, Robert and Ailawadhi, Sikander and Omel, James and Hardin, James W and Narang, Mohit and Toomey, Kathleen and Gasparetto, Cristina and Wagner, Lynne I and Terebelo, Howard and Mouro, Jorge and Dhanasiri, Sujith and Liu, Liang and Yu, Edward and Jagannath, Sundar},
  title = {The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2024.05.021}
}
Kostenlos starten →